Keyphrases
End-stage Renal Disease Patients
45%
Sleep-disordered Breathing
45%
Central Sleep Apnea
41%
Obstructive Sleep Apnea
40%
Patient's Sleep
25%
Sleep Medicine
25%
Cardiovascular Disease
25%
Sleep Apnea
22%
Sleep Disorders
22%
Heart Failure
19%
End-stage Renal Disease
17%
Coronary Artery Disease
12%
Cardiovascular Outcomes
12%
P2Y12 Inhibitors
11%
Intravenous Lipid Emulsion Therapy
11%
Heart Failure Admission
11%
Beta-blockers
11%
Neurological Outcome
11%
Clinical Impact
11%
High-dose Insulin
11%
Transvenous Phrenic Nerve Stimulation
11%
Demographic Risk Factors
11%
Cardiogenic Shock
11%
Billing
11%
Financial Impact
11%
Disorders Diagnosis
11%
Bronchiolitis Obliterans Syndrome
11%
Castleman Disease
11%
Patient Characteristics
11%
Middle-aged
11%
Clinical Risk Factors
11%
Pediatric Patients
11%
Mucosal Erosion
11%
Pemphigus
11%
Paraneoplastic Pemphigus
11%
Failure Interaction
11%
Acute Dyspnea
11%
Quality Measures
11%
Calcium Channel Blockers
11%
Patient Impact
11%
Shock-induced
11%
Restless Legs Syndrome
9%
Insomnia
9%
Older Men
9%
Intravenous Lipid Emulsion
9%
United States Renal Data System (USRDS)
9%
Heart Failure Patients
9%
Decreased Risk
8%
Insurer
8%
Ticagrelor
7%
Medicine and Dentistry
Obstructive Sleep Apnea
100%
End Stage Renal Disease
45%
Cardiovascular Disease
35%
Cardiovascular System
31%
Sleep Medicine
31%
Heart Failure
30%
Central Sleep Apnea
30%
Sleep Disorder
20%
Bronchiolitis Obliterans
11%
Neurostimulation
11%
Middle Age
11%
Pediatrics Patient
11%
Angiofollicular Lymph Node Hyperplasia
11%
Phrenic Nerve
11%
Paraneoplastic Pemphigus
11%
Venous Ulcer
11%
Pemphigus
11%
Dyspnea
11%
Racial Disparity
11%
Cardiovascular Risk
11%
Health Care Cost
8%
Airway Obstruction
7%
Restless Legs Syndrome
6%
Diabetes
6%
Inguinal Lymph Node
5%
Lymphadenopathy
5%
Azithromycin
5%
Lymph Node Biopsy
5%
Desmoglein
5%
Immunoglobulin G Antibody
5%
Emergency Department
5%
Rituximab
5%
Bronchus Mucosa
5%
Pulmonary Function Testing
5%
Obstructive Lung Disease
5%
Myocardial Infarction
5%
Apoplexy
5%
Medicare
5%
Outpatient
5%
Cardiac Dysrhythmia
5%
Peritoneal Dialysis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Sleep Disordered Breathing
65%
End Stage Renal Disease
45%
Sleep Disorder
30%
Central Sleep Apnea Syndrome
29%
Heart Failure
28%
Cardiovascular Disease
17%
Sleep Medicine
15%
Cardiovascular Risk
12%
Calcium Channel Blocker
11%
Toxic Injury
11%
Beta Adrenergic Receptor Blocking Agent
11%
Cardiogenic Shock
11%
Lipid Emulsion
11%
Restless Legs Syndrome
8%
Comorbidity
6%
Cardiovascular Disease
5%
Heart Infarction
5%
